By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics this week said that has launched a study of its Epi proColon test to examine adoption patterns in the market.

The German molecular diagnostics firm launched the colorectal cancer test in Europe in 2009. It is currently being marketed by Epigenomics to privately insured individuals and self-payors in Germany, Austria, and Switzerland and through distributors in other markets, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.